As of May 27
| +0.17 / +3.98%|
The 2 analysts offering 12-month price forecasts for Tetraphase Pharmaceuticals Inc have a median target of 14.50, with a high estimate of 21.00 and a low estimate of 8.00. The median estimate represents a +226.58% increase from the last price of 4.44.
The current consensus among 6 polled investment analysts is to Hold stock in Tetraphase Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.